Cite
HARVARD Citation
Dimopoulos, M. et al. (2017). Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth. British journal of haematology. pp. 896-905. [Online].